RECITALSCancer Collaboration Agreement • November 14th, 2001 • Exelixis Inc • Services-commercial physical & biological research • New York
AMENDED AND RESTATED CANCER COLLABORATION AGREEMENT BETWEEN EXELIXIS, INC. AND BRISTOL-MYERS SQUIBB COMPANYCancer Collaboration Agreement • February 25th, 2004 • Exelixis Inc • Services-commercial physical & biological research • New York
THIS AMENDED AND RESTATED CANCER COLLABORATION AGREEMENT (the “Amended and Restated Agreement”) is made and entered into as of December 15, 2003 (the “Amendment Effective Date”) by and between EXELIXIS, INC., a Delaware corporation having its principal place of business at 170 Harbor Way, P.O. Box 511, South San Francisco, California 94083-0511 (“Exelixis”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, 10154 (“BMS”). Exelixis and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
